-+ 0.00%
-+ 0.00%
-+ 0.00%

Beam Therapeutics selects 60 mg BEAM-302 for pivotal development; Phase 1/2 trial mean steady-state total AAT climbs to 16.1 µM at 60 mg

Reuters·03/25/2026 11:03:24

Please log in to view news